These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 22543534)

  • 1. Imaging and clinical measurements.
    Pineda C; Maksymowych WP
    Am J Med Sci; 2012 May; 343(5):345-9. PubMed ID: 22543534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity.
    Korkosz M; Gąsowski J; Leszczyński P; Pawlak-Buś K; Jeka S; Siedlar M; Grodzicki T
    Scand J Rheumatol; 2014; 43(1):43-8. PubMed ID: 24447112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
    Song IH; Rudwaleit M; Listing J; Sieper J
    Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.
    Pham T; Landewé R; van der Linden S; Dougados M; Sieper J; Braun J; Davis J; Rudwaleit M; Collantes E; Burgos-Vargas R; Edmonds J; Olivieri I; van der Horst-Bruinsma I; Mielants H; Stone M; Emery P; van der Heijde D
    Ann Rheum Dis; 2006 Dec; 65(12):1620-5. PubMed ID: 16464984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of circulating endothelial and platelet microparticles in men with ankylosing spondylitis.
    Sari I; Bozkaya G; Kirbiyik H; Alacacioglu A; Ates H; Sop G; Can G; Taylan A; Piskin O; Yildiz Y; Akkoc N
    J Rheumatol; 2012 Mar; 39(3):594-9. PubMed ID: 22247348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index in Turkish patients with ankylosing spondylitis: relationship with disease activity and quality of life.
    Zahiroglu Y; Ulus Y; Akyol Y; Tander B; Durmus D; Bilgici A; Kuru O
    Int J Rheum Dis; 2014 Feb; 17(2):173-80. PubMed ID: 24576273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to define remission in ankylosing spondylitis?
    Sieper J
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i93-5. PubMed ID: 22460148
    [No Abstract]   [Full Text] [Related]  

  • 9. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor.
    Machado P; Landewé RB; Braun J; Baraliakos X; Hermann KG; Hsu B; Baker D; van der Heijde D
    Ann Rheum Dis; 2012 Dec; 71(12):2002-5. PubMed ID: 22915615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor necrosis factor therapies reduce serum macrophage inflammatory protein-1alpha in ankylosing spondylitis.
    Akbulut H; Koca SS; Ozgen M; Isik A
    J Rheumatol; 2010 May; 37(5):1073-4. PubMed ID: 20439531
    [No Abstract]   [Full Text] [Related]  

  • 11. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
    Baraliakos X; Brandt J; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2005 Dec; 53(6):856-63. PubMed ID: 16342093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The "knowns" and "unknowns" of biologic therapy in ankylosing spondylitis.
    Gensler L; Inman R; Deodhar A
    Am J Med Sci; 2012 May; 343(5):360-3. PubMed ID: 22543538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.
    Chen CH; Liao HT; Chen HA; Liu CH; Liang TH; Wang CT; Tsai CY; Chou CT
    Rheumatology (Oxford); 2010 Feb; 49(2):264-70. PubMed ID: 20008091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.
    Braun J; Davis J; Dougados M; Sieper J; van der Linden S; van der Heijde D;
    Ann Rheum Dis; 2006 Mar; 65(3):316-20. PubMed ID: 16096329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional DMARD therapy (methotrexate-sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: a real-life experience.
    Can M; Aydın SZ; Niğdelioğlu A; Atagündüz P; Direskeneli H
    Int J Rheum Dis; 2012 Dec; 15(6):526-30. PubMed ID: 23253235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
    Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
    Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
    van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
    Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme.
    Fernández-Espartero C; de Miguel E; Loza E; Tomero E; Gobbo M; Descalzo MA; Collantes-Estévez E; Mulero J; Muñoz-Fernández S; Zarco P; Carmona L;
    Ann Rheum Dis; 2014 Jul; 73(7):1350-5. PubMed ID: 23709245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up.
    Kneepkens EL; Krieckaert CL; van der Kleij D; Nurmohamed MT; van der Horst-Bruinsma IE; Rispens T; Wolbink GJ
    Ann Rheum Dis; 2015 Oct; 74(10):1825-9. PubMed ID: 24812290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
    Visvanathan S; Wagner C; Marini JC; Baker D; Gathany T; Han J; van der Heijde D; Braun J
    Ann Rheum Dis; 2008 Apr; 67(4):511-7. PubMed ID: 17644552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.